Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Our Editorial Board

Editor's pick

13-07-2018 | Castration-resistant prostate cancer | News

Pembrolizumab tested in previously treated mCRPC

The PD-1 inhibitor pembrolizumab shows antitumor activity in patients with previously treated metastatic castration-resistant prostate cancer, indicate results from the KEYNOTE-028 and KEYNOTE-199 trials.

31-05-2018 | Genitourinary cancers | Themed collection | Collection

Best of JCO™ 2018: Genitourinary Cancer Edition

The content compiled here represents some of the most-accessed original research from recently published Journal of Clinical Oncology articles across a range of topics including prostate and bladder cancer. 

28-06-2018 | Surgery | Editorial | Article

Breast cancer-related lymphedema management: Current state and future directions

Breast cancer-related lymphedema is a debilitating complication of breast cancer surgery. Babak Mehrara (Memorial Sloan Kettering Cancer Center, NY, USA) outlines the current state of lymphedema management and poses some questions for the future.

Specialty

Latest from across the site

17-07-2018 | Survival | News

News in brief

Alcohol use, physical inactivity after cancer diagnosis linked to poor survival

US researchers stress the need for effective interventions to reduce alcohol use and increase physical activity in patients with advanced cancer.

17-07-2018 | Melanoma | News

‘Dramatically improved’ OS with checkpoint inhibitor use for melanoma brain metastases

Melanoma patients with brain metastases can expect to live longer following the incorporation of checkpoint inhibitors and BRAF-targeted therapies into standard care than their counterparts treated prior to the approval of these agents, suggests an analysis of the US National Cancer Database.

Source:

Cancer Immunol Res 2018; doi:10.1158/2326-6066.CIR-18-0067

16-07-2018 | EMA | News

approvalsWatch

EMA recommends two CAR T-cell therapies for approval

These decisions are reported here

16-07-2018 | Liver cancer | News

Ultrasound-induced targeted doxorubicin delivery feasible for liver tumors

Targeted delivery of doxorubicin using a thermosensitive liposomal preparation triggered by focused ultrasound appears to be a viable option for the treatment of liver tumors, according to the proof-of-concept TARDOX study.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30332-2, 10.1016/S1470-2045(18)30419-4

13-07-2018 | Renal cell carcinoma | News

Germline mutations detected in advanced RCC patients

Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.1986

13-07-2018 | Castration-resistant prostate cancer | News

Pembrolizumab tested in previously treated mCRPC

The PD-1 inhibitor pembrolizumab shows antitumor activity in patients with previously treated metastatic castration-resistant prostate cancer, indicate results from the KEYNOTE-028 and KEYNOTE-199 trials.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy232, ASCO Annual Meeting 2018; Chicago, Illinois, USA

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

This program was made possible thanks to independent educational sponsorship from MorphoSys.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits